Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Schizophrenia

  Free Subscription


24.02.2020

1 Biol Psychiatry
2 J Clin Psychopharmacol
1 Mol Psychiatry
1 PLoS One
6 Psychiatry Res
1 Psychol Med
2 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Biol Psychiatry

  1. MENNIGEN E, Bearden CE
    Psychosis Risk and Development: What Do We Know From Population-Based Studies?
    Biol Psychiatry. 2019 Dec 20. pii: S0006-3223(19)31938.
    PubMed     Text format     Abstract available


    J Clin Psychopharmacol

  2. NOEL MC, Powell V, Burton L, Panda R, et al
    Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review.
    J Clin Psychopharmacol. 2019;39:380-385.
    PubMed     Text format     Abstract available

  3. ENGELKE C, Cordes J, Kahl KG, Schmidt-Kraepelin C, et al
    Attitudes Toward Long-Term Medication Use-A Comparison Between Concerned Populations and a Sample From the German General Population: An Example of Real World Evidence.
    J Clin Psychopharmacol. 2019;39:357-361.
    PubMed     Text format     Abstract available


    Mol Psychiatry

  4. ANDREOU C, Borgwardt S
    Structural and functional imaging markers for susceptibility to psychosis.
    Mol Psychiatry. 2020 Feb 17. pii: 10.1038/s41380-020-0679.
    PubMed     Text format     Abstract available


    PLoS One

  5. CERNIS E, Freeman D, Ehlers A
    Describing the indescribable: A qualitative study of dissociative experiences in psychosis.
    PLoS One. 2020;15:e0229091.
    PubMed     Text format     Abstract available


    Psychiatry Res

  6. SALMINEN I, Read S, Hurd P, Crespi B, et al
    Does SNORD116 mediate aspects of psychosis in Prader-Willi syndrome? Evidence from a non-clinical population.
    Psychiatry Res. 2020;286:112858.
    PubMed     Text format     Abstract available

  7. LE L, R K, B M, Mj G, et al
    Risk of schizophrenia in relatives of individuals affected by schizophrenia: A meta-analysis.
    Psychiatry Res. 2020;286:112852.
    PubMed     Text format     Abstract available

  8. SHIMADA T, Ito S, Makabe A, Yamanushi A, et al
    Aerobic exercise and cognitive functioning in schizophrenia: Results of a 1-year follow-up from a randomized controlled trial.
    Psychiatry Res. 2020;286:112854.
    PubMed     Text format     Abstract available

  9. TOH WL, McCarthy-Jones S, Copolov D, Rossell SL, et al
    Corrigendum to 'Have we overlooked the significance of multinodal hallucinations in schizophrenia?' [Psychiatry Research 279 (2019) 358-360].
    Psychiatry Res. 2020;286:112849.
    PubMed     Text format    

  10. FISHER E, Wood SJ, Upthegrove R, Aldred S, et al
    Designing a feasible exercise intervention in first-episode psychosis: Exercise quality, engagement and effect.
    Psychiatry Res. 2020;286:112840.
    PubMed     Text format     Abstract available

  11. ALLE MC, Berna F, Danion JM, Berntsen D, et al
    Seeing or hearing one's memories: Manipulating autobiographical memory imagery in schizophrenia.
    Psychiatry Res. 2020;286:112835.
    PubMed     Text format     Abstract available


    Psychol Med

  12. COLIZZI M, Ruggeri M, Lasalvia A
    Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review.
    Psychol Med. 2020 Feb 17:1-22. doi: 10.1017/S0033291720000148.
    PubMed     Text format     Abstract available


    Schizophr Res

  13. VERMA M, Sahoo S, Nehra R, Grover S, et al
    Does clozapine improves cognition in patients with treatment resistant schizophrenia?: An exploratory study.
    Schizophr Res. 2020 Feb 13. pii: S0920-9964(20)30078.
    PubMed     Text format    

  14. FREEDMAN R, Olsen-Dufour AM, Olincy A
    P50 inhibitory sensory gating in schizophrenia: analysis of recent studies.
    Schizophr Res. 2020 Feb 12. pii: S0920-9964(20)30079.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: